Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 6 studies | 23% ± 6% | |
mesothelial cell | 5 studies | 31% ± 16% | |
endothelial cell | 5 studies | 28% ± 7% | |
epithelial cell | 4 studies | 28% ± 3% | |
astrocyte | 4 studies | 30% ± 8% | |
microglial cell | 3 studies | 19% ± 1% | |
ciliated cell | 3 studies | 20% ± 3% | |
hepatocyte | 3 studies | 41% ± 33% | |
GABAergic neuron | 3 studies | 41% ± 3% | |
glutamatergic neuron | 3 studies | 50% ± 4% | |
oligodendrocyte precursor cell | 3 studies | 26% ± 7% | |
macrophage | 3 studies | 21% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 36% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2575.65 | 1445 / 1445 | 100% | 40.97 | 183 / 183 |
ovary | 100% | 2350.34 | 180 / 180 | 100% | 28.36 | 430 / 430 |
stomach | 100% | 1843.14 | 359 / 359 | 100% | 37.87 | 286 / 286 |
lung | 100% | 2295.99 | 578 / 578 | 100% | 32.25 | 1154 / 1155 |
intestine | 100% | 2349.06 | 966 / 966 | 100% | 34.80 | 526 / 527 |
bladder | 100% | 3488.90 | 21 / 21 | 100% | 31.75 | 503 / 504 |
uterus | 100% | 3374.50 | 170 / 170 | 100% | 32.84 | 458 / 459 |
breast | 100% | 2328.48 | 459 / 459 | 100% | 34.53 | 1115 / 1118 |
prostate | 100% | 2835.54 | 245 / 245 | 100% | 34.59 | 500 / 502 |
pancreas | 100% | 1323.75 | 328 / 328 | 99% | 25.69 | 177 / 178 |
liver | 100% | 7056.89 | 226 / 226 | 99% | 23.93 | 402 / 406 |
thymus | 100% | 2571.81 | 653 / 653 | 99% | 23.23 | 599 / 605 |
brain | 98% | 1332.15 | 2593 / 2642 | 100% | 24.82 | 705 / 705 |
kidney | 100% | 1880.33 | 89 / 89 | 98% | 20.69 | 883 / 901 |
skin | 100% | 2456.70 | 1809 / 1809 | 98% | 27.98 | 462 / 472 |
adrenal gland | 100% | 2202.37 | 258 / 258 | 94% | 16.66 | 216 / 230 |
adipose | 100% | 2416.63 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2019.44 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 23.11 | 29 / 29 |
muscle | 100% | 3710.53 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2561.76 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 27.38 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.75 | 1 / 1 |
heart | 99% | 2667.83 | 850 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 93% | 16.10 | 74 / 80 |
peripheral blood | 80% | 1328.17 | 747 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0031124 | Biological process | mRNA 3'-end processing |
GO_0001111 | Biological process | RNA polymerase II promoter clearance |
GO_0010564 | Biological process | regulation of cell cycle process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0097550 | Cellular component | transcription preinitiation complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0000993 | Molecular function | RNA polymerase II complex binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0099122 | Molecular function | RNA polymerase II C-terminal domain binding |
Gene name | RPRD1B |
Protein name | Regulation of nuclear pre-mRNA domain-containing protein Regulation of nuclear pre-mRNA domain containing 1B Regulation of nuclear pre-mRNA domain-containing protein 1B (Cell cycle-related and expression-elevated protein in tumor) |
Synonyms | C20orf77 CREPT |
Description | FUNCTION: Interacts with phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and participates in dephosphorylation of the CTD by RPAP2. Transcriptional regulator which enhances expression of CCND1. Promotes binding of RNA polymerase II to the CCDN1 promoter and to the termination region before the poly-A site but decreases its binding after the poly-A site. Prevents RNA polymerase II from reading through the 3' end termination site and may allow it to be recruited back to the promoter through promotion of the formation of a chromatin loop. Also enhances the transcription of a number of other cell cycle-related genes including CDK2, CDK4, CDK6 and cyclin-E but not CDKN1A, CDKN1B or cyclin-A. Promotes cell proliferation. . FUNCTION: Interacts with phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and participates in dephosphorylation of the CTD. . FUNCTION: Interacts with phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and participates in dephosphorylation of the CTD. . |
Accessions | ENST00000614670.1 ENST00000622494.1 A0A087WUK3 Q9NQG5 ENST00000449186.2 ENST00000373433.9 ENST00000495457.1 E9PQF3 A0A087X2D2 ENST00000462548.6 A2A2M0 E9PIQ9 |